抗ウイルス療法：パイプラインと競合動向

Abstract

Antiviral Therapeutics: Pipelines and Competitive Dynamics assesses the compounds, the clinical data, the companies, and the market-shifting developments in the antiviral therapeutic category. Sales of antiviral agents currently constitute 25% of the anti-infective drug market. The ability of viruses to develop resistance against drugs, coupled with sub-optimal treatment outcomes as a result of failure of patients to comply with the full course of therapy, will continue to provide the commercial and medical incentive for intense R&D activity.

Until recently, much of the effort to develop new antiviral agents was directed toward improved agents for the treatment of HIV and Hepatitis C (HCV). While these indications continue to attract research dollars and to make measurable progress with respect to dosing, deliverability, and efficacy, several new developments have reignited interest in antiviral disease R&D. These include concern about the evolution of avian influenza into a lethal pandemic and recent approvals for vaccines against certain strains of Human Papilloma Virus (HPV) that are associated with high rates of cervical cancer.

Antiviral Therapeutics: Pipelines and Competitive Dynamics surveys the 5 major viral disease categories and their sub-indications- HIV, Hepatitis, Herpes Viruses, Human Papilloma Viruses, and Respiratory Viruses.

For each indication, the report provides:

• Pathophysiology, incidence and prevalence, symptoms and sequelae.
• Assessment of current treatment options.
• Assessment of unmet medical need.
• Assessment of compounds in development (by agent and by mechanism of action).
• Profiles of companies active in antiviral R&D

Table of Contents

Chapter 1. Viral Disorder and Therapeutic Approaches

• 1.1. Commom Viral Infections
• 1.2. Vaccines or Antiviral Drugs
• 1.3. Inhibition of Viral Infection of Cells
• 1.4. Inhibition of Viral Processing

Chapter 2. Review of Major Viral Disorders

• 2.1. Human Immunodeficiency Virus
• 2.2. Hepatitis Viruses
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
• 2.3. Herpes Viruses
  • Herpes Simplex Virus
  • Varicella-Zoster Virus
  • Cytomegalovirus
  • Epstein-Barr Virus
• 2.4. Human Papilloma Virus
• 2.5. Respiratory Viruses
  • Influenza
  • Respiratory Syncytial Virus
  • Coronaviruses

Chapter 3. Current Treatment

• 3.1. Human Immunodeficiency Virus
  • HIV Reverse Transcriptase Inhibitors
  • HIV Protease Inhibitors
  • HIV Fusion Inhibitors
• 3.2. Hepatitis Viruses
  • Vaccine Treatments
  • Cytokines
  • Antiviral Agents
• 3.3. Herpes Viruses
  • Viral Replication Inhibitors
• 3.4. Human Papilloma Viruses
• 3.5. Respiratory Viruses
  • Vaccines
  • Neuraminidase Inhibitors
  • Antibodies
  • Inosine Monophosphate Dehydrogenase Inhibitors

Chapter 4. Compounds in Development: New Antiviral Agents

• 4.1. Human Immunodeficiency Virus
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • Cell Entry Blockers
  • HIV Replication Inhibitors
  • HIV Integrase Inhibitors
  • HIV Maturation Inhibitors
  • Combination Therapies
• 4.2. Hepatitis C
  • HCV Protease Inhibitors
  • Polymerase Inhibitors
  • Immunostimulants: Interferons
  • Toll-like Receptor Agonists
  • Other Immunoregulators
  • Viral Replication Inhibitors
• 4.2. Mechanistic Issues in Atherogenic Dyslipidemia
  • Anti-Atherogenic Effects of High-Density Lipoprotein
  • Metabolic Syndrome, High-Density Lipoprotein, and Triglycerides
• 4.3. Hepatitis B
  • DNA Polymerase Inhibitors
  • Other Agents
• 4.4. Herpes Viruses
  • Vaccines
  • Viral Replication Inhibitors
  • Viral Uptake Inhibitors
  • DNA Synthesis Inhibitors
  • Other Agents
• 4.5. Human Papilloma Viruses
  • Vaccines
  • Interferons
  • Immunomodulators
• 4.6. Influenza
  • New Drugs
  • New Vaccines
  • H5N1 Influenza Vaccines

Chapter 5. Company R&D Profiles

• 5.1. Abbott
• 5.2. Achillion
• 5.3. Boehringer Ingelheim
• 5.4. Biota Holdings
• 5.5. Bristol-Myers Squibb
• 5.6. Chiron
• 5.7. Coley
• 5.8. Enzo Biochem
• 5.9. Gilead Sciences
• 5.10. GlaxoSmithKline
• 5.11. Hoffmann-La Roche
• 5.12. Idenix Pharmaceuticals
• 5.13. Japan Tobacco
• 5.14. Johnson & Johnson
• 5.15. Medivir
• 5.16. Merck & Co.
• 5.17. Novartis AG
• 5.18. Panacos Pharmaceuticals
• 5.19. Pfizer
• 5.20. sanofi pasteur
• 5.21. Schering-Plough
• 5.22. Trimeris
• 5.23. Valeant
• 5.24. Vertex
• 5.25. ViroPharma Incorporated

Chapter 6. EXPERT INTERVIEWS: Dr. Michael G. Cordingley, Boehringer Ingelheim (Canada) Ltd.; Dr. Stef Heylen, Tibotec; Professor Bertil Samuelsson, Medivir AB

• 6.1. HIV
• 6.2. Hepatitis
• 6.3. Other Viral Infections
• 6.4. Other Issues

References

Glossary

Company Index with Web Sites